|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.88 USD | +1.08% |
|
-29.98% | +1.28% |
Company Valuation: Monte Rosa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 949.7 | 368.3 | 282.8 | 426.4 | 1,021 | 1,342 | - | - |
| Change | - | -61.22% | -23.21% | 50.74% | 139.48% | 31.39% | - | - |
| Enterprise Value (EV) | 603.6 | 105.5 | 50.43 | 54.22 | 1,021 | 1,342 | 1,342 | 1,342 |
| Change | - | -82.52% | -52.19% | 7.5% | 1,783.24% | 31.39% | 0% | 0% |
| P/E | -6.9x | -3.31x | -2.15x | -7.08x | -34.1x | -8.51x | -7.11x | -7.34x |
| PBR | 2.75x | 1.32x | 1.58x | 1.91x | - | - | - | - |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.6x | -0x | -0.4x | 2.31x |
| Capitalization / Revenue | - | - | - | 5.64x | 8.26x | 40.6x | 47.8x | 15.7x |
| EV / Revenue | - | - | - | 0x | 0x | 40.6x | 47.8x | 15.7x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -6.38x | -5.31x | -5.15x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -15.7x | -25x | -28.3x |
| FCF Yield | -7.28% | -28.6% | -22.2% | 8.91% | -2.69% | -6.38% | -4.01% | -3.53% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | -1.865 | -2.235 | -2.164 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 75.62 | 123.7 | 33.08 | 28.05 | 85.5 |
| EBITDA | -70.75 | -108.6 | -137.1 | -72.99 | - | - | - | - |
| EBIT 1 | -72.88 | -112.4 | -143.3 | -81.11 | -54.21 | -210.2 | -252.8 | -260.4 |
| Net income 1 | -73.96 | -108.5 | -135.4 | -72.7 | -38.63 | -189.1 | -237.9 | -246.4 |
| Net Debt | -346.1 | -262.8 | -232.4 | -372.1 | - | - | - | - |
| Reference price 2 | 20.42 | 7.61 | 5.65 | 6.94 | 15.68 | 15.88 | 15.88 | 15.88 |
| Nbr of stocks (in thousands) | 46,506 | 48,399 | 50,062 | 61,436 | 65,118 | 84,479 | - | - |
| Announcement Date | 29/3/22 | 16/3/23 | 14/3/24 | 20/3/25 | 17/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.51x | - | - | - | 1.33B | |
| 33.27x | 5.94x | 17.68x | 0.96% | 48.7B | |
| -22.15x | 304.02x | -19.9x | -.--% | 42.05B | |
| 29.93x | 2.99x | 12.91x | -.--% | 38.26B | |
| 43.85x | 4.94x | 27.58x | -.--% | 37.5B | |
| 29.67x | 8.57x | 21.53x | 0.39% | 31.44B | |
| 33.27x | 5.44x | 24.74x | -.--% | 16.33B | |
| 23.25x | 2.04x | 8.83x | 1.16% | 13.98B | |
| 53.86x | 3.78x | 14.82x | -.--% | 12.68B | |
| Average | 24.05x | 42.22x | 13.52x | 0.31% | 26.92B | |
| Weighted average by Cap. | 24.56x | 57.31x | 12.22x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GLUE Stock
- Valuation Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
